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Abstract
Background: The long-term efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist,
were investigated in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Methods: In two double-blind, 52-week studies, ACCLAIM/COPD I (n = 843) and II (n = 804), patients were
randomised to inhaled aclidinium 200 μg or placebo once-daily. Patients were required to have a post-
bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity ratio of ≤70% and FEV1 <80% of the
predicted value. The primary endpoint was trough FEV1 at 12 and 28 weeks. Secondary endpoints were health status
measured by St George’s Respiratory Questionnaire (SGRQ) and time to first moderate or severe COPD exacerbation.
Results: At 12 and 28 weeks, aclidinium improved trough FEV1 versus placebo in ACCLAIM/COPD I (by 61 and 67 mL;
both p < 0.001) and ACCLAIM/COPD II (by 63 and 59 mL; both p < 0.001). More patients had a SGRQ improvement ≥4
units at 52 weeks with aclidinium versus placebo in ACCLAIM/COPD I (48.1% versus 39.5%; p = 0.025) and ACCLAIM/
COPD II (39.0% versus 32.8%; p = 0.074). The time to first exacerbation was significantly delayed by aclidinium in
ACCLAIM/COPD II (hazard ratio [HR] 0.7; 95% confidence interval [CI] 0.55 to 0.92; p = 0.01), but not ACCLAIM/COPD I
(HR 1.0; 95% CI 0.72 to 1.33; p = 0.9). Adverse events were minor in both studies.
Conclusion: Aclidinium is effective and well tolerated in patients with moderate to severe COPD.
Trial registration: ClinicalTrials.gov: NCT00363896 (ACCLAIM/COPD I) and NCT00358436 (ACCLAIM/COPD II).
Keywords: Aclidinium bromide anticholinergic, chronic obstructive pulmonary disease, long-acting muscarinic
antagonist
Background
Vagal cholinergic tone is the major reversible contributor
to airway narrowing in chronic obstructive pulmonary
disease (COPD); therefore, inhaled anticholinergic agents
play a key role in the treatment of this disorder [1]. The
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) recommends long-acting bronchodilators for
the management of patients with stable COPD [2]; how-
ever, only one long-acting anticholinergic agent, tiotro-
pium bromide, is available to date. Given the variability
in individual patient responses to therapy in terms of effi-
cacy and tolerability, and individual patient preferences
for different formulations and delivery devices, the
investigation of additional long-acting anticholinergic
treatment options is warranted.
Aclidinium bromide is a novel, long-acting muscarinic
antagonist currently in development for the treatment of
COPD. Early studies in preclinical models indicated that
aclidinium had potent bronchodilatory effects [3] and an
inhibitory effect on mucus hypersecretion [4]. Preclinical
and clinical studies have demonstrated the rapid hydrolysis
of aclidinium in human plasma into inactive metabolites
[5,6], suggesting a reduced propensity for systemic side
effects. In Phase II studies, aclidinium showed long-lasting
bronchodilatory activity and good tolerability with a low
incidence of cardiovascular side effects [7,8].
This paper reports data from two Phase III studies,
ACCLAIM/COPD (AClidinium CLinical trial Assessing
efficacy and safety In Moderate to severe COPD patients)
I and II, to assess the long-term efficacy and safety of
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Methods
Subjects
Male and non-pregnant, non-lactating female patients
aged ≥40 years were included if they had a diagnosis of
COPD according to GOLD criteria [2], with a post-
bronchodilator forced expiratory volume in 1 second
(FEV1)/forced vital capacity (FVC) ratio of ≤70% and
FEV1 <80% of the predicted value [9]. The pre-dose
FEV1 at randomisation had to be within 80-120% of the
pre-bronchodilator FEV1 at screening. All patients were
current or previous cigarette smokers with a smoking
history of ≥10 pack-years. A previous history of exacer-
bations was not required.
Key exclusion criteria were: history or current diagnosis
of asthma, allergic rhinitis or atopy; blood eosinophil
count >600 cell/mm
3; respiratory tract infection or
COPD exacerbation within 6 weeks prior to screening or
during the run-in period; hospitalisation for an acute
COPD exacerbation within 3 months prior to screening;
use of long-term oxygen therapy; clinically significant
respiratory diseases other than COPD; unstable cardiac
conditions.
Inhaled salbutamol was permitted on an as-needed basis,
but had to be discontinued 6 hours prior to and during a
study visit. The following concomitant COPD medications
were allowed, provided their administration had been
stable for at least 4 weeks prior to screening: inhaled corti-
costeroids or oral sustained-release theophyllines; oral or
parenteral corticosteroids at maximal doses equivalent to
10 mg/day of prednisone or 20 mg every other day; oxygen
therapy (<15 hours per day).
The studies were performed in accordance with the
Declaration of Helsinki, International Conference on Har-
monisation Good Clinical Practice Guidelines and local
regulations. Prior to study initiation at each centre, the
protocol was approved by an Independent Ethics Commit-
tee or Institutional Review Board. All patients gave written
informed consent. The studies were registered with Clini-
calTrials.gov as follows: NCT00363896 (ACCLAIM/
COPD I) and NCT00358436 (ACCLAIM/COPD II).
Study design
Two identical 52-week, double-blind, randomised, pla-
cebo-controlled, parallel-group studies were performed
as regulatory organisations require replicated data.
ACCLAIM/COPD I was conducted at 139 centres in 16
European countries and ACCLAIM/COPD II at 119 sites
in 7 countries (primarily in North America). After screen-
ing, patients underwent a 14-day run-in period to assess
their disease stability. Eligible patients were randomised in
a 3:1 ratio to receive aclidinium 200 μg or matching
placebo once-daily via the Genuair
® inhaler, a novel multi-
dose dry powder inhaler [10].
It was estimated that a total sample size of 820 patients
per study (615 and 205 patients in the aclidinium and
placebo arms, respectively) would provide at least 90%
power to detect a difference of 100 mL in trough FEV1
between the two arms at 12 and 28 weeks, with a two-
sided 5% level of significance and assuming a standard
deviation of 310 mL [7].
Assessments
Spirometry was conducted according to American Thor-
acic Society (ATS)/European Respiratory Society (ERS)
recommendations [11] at 1 hour pre-dose and immediately
before dosing during study visits on Day 1 (baseline); Day
2; Week 1; every month up to Week 20; and thereafter
every 2 months until Week 52. Measurements were also
performed at 0.25, 0.5, 1, 2 and 3 hours post-dose on Day
1; and at 0.5, 1, 2 and 3 hours post-dose at Weeks 1, 4, 8,
12, 28, 44 and 52. Sites were provided with identical spiro-
metry equipment, a detailed study manual and training.
A centralised quality-assurance review of all spirometry
data was conducted throughout the study. The spirometry
data were electronically transmitted to a data-management
centre where an independent, blinded, spirometric expert
reviewed the acceptability and repeatability of the data
according to ATS/ERS acceptability criteria.
Health status and dyspnoea were evaluated pre-dose on
Day 1 (baseline) and at Weeks 12, 28, 44 and 52 using
the St George’s Respiratory Questionnaire (SGRQ; self
administered) and Baseline/Transitional Dyspnoea Index
(BDI/TDI; administered by an independent reviewer).
Data on morning and evening peak expiratory flow,
COPD symptoms over 24 hours (breathlessness on a scale
of 0 to 4; cough, sputum production and wheezing on a
scale of 0 to 3), use of daily rescue medication and conco-
mitant medication were recorded in the patient’s diary and
reviewed by the investigator at each visit to identify the
occurrence of a COPD exacerbation. COPD exacerbations
were defined as an increase in COPD symptoms over at
least two consecutive days, associated with increased use of
bronchodilators (mild exacerbation), treatment with anti-
biotics and/or systemic corticosteroids (moderate exacerba-
tion) or leading to hospitalisation (severe exacerbation).
Safety was assessed by adverse-event (AE) monitoring,
physical examination, blood pressure, 12-lead electrocar-
diogram (ECG) and laboratory data (haematology, bio-
chemistry and urinalysis).
Statistical analysis
Efficacy analyses were performed on the intent-to-treat
population, defined as all randomised patients who
received at least one dose of study medication and who
had a baseline and at least one post-baseline trough FEV1
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domised patients who received at least one dose of study
medication.
FEV1, FVC, inspiratory capacity, peak expiratory flow
and change from baseline in SGRQ scores were analysed
using an analysis of covariance (ANCOVA) model with
treatment and sex as factors, and baseline values and
age as covariates; the same model, without adjustment
for age and sex, was used to analyse the change from
baseline in dyspnoea, COPD symptom scores and use of
daily rescue medication. Missing data were imputed
using a last observation carried forward approach. The
minimal clinically importantd i f f e r e n c e( M C I D )f o rt h e
SGRQ and TDI is 4 units and 1 unit, respectively
[12,13]. A logistic regression model was used to analyse
the number of patients with a ≥4-unit decrease in
SGRQ total score (with adjustment for age, sex and
baseline values) and a ≥1-unit improvement in TDI total
score (with adjustment for baseline values). Time to first
moderate or severe COPD exacerbation was evaluated
using a Cox Proportional Hazards model adjusted for
age, sex and COPD severity at screening.
The primary endpoint was trough FEV1 at Weeks 12
and 28 to fulfil US and European regulatory requirements,
respectively. Secondary endpoints were: the number of
patients who achieved a clinically relevant improvement in
health-related quality of life at 52 weeks, as measured by a
≥4-unit decrease from baseline on the SGRQ total score;
and time to first moderate or severe COPD exacerbation.
Results
Study population
Patient disposition in the two studies is illustrated in
Figure 1. Table 1 shows demographics and disease status
at baseline. Compared with ACCLAIM/COPD I, in
ACCLAIM/COPD II, there were slightly more females
and fewer smokers, the post-bronchodilator FEV1 was
slightly lower and the bronchodilator reversibility was
slightly higher. The percentage of patients who continued
to use inhaled corticosteroids in the aclidinium and pla-
cebo groups was 39.1% and 40.0%, respectively, in
ACCLAIM/COPD I, and 40.2% and 44.3%, respectively,
in ACCLAIM/COPD II. In both studies, a lower propor-
tion of patients discontinued treatment in the aclidinium
arm compared with the placebo arm; the difference in
withdrawal rates between the study arms was greater in
ACCLAIM/COPD II (25.7% versus 42.2%, respectively;
16.5% difference) than in ACCLAIM/COPD I (14.2%
versus 21.8%, respectively; 7.6% difference).
Efficacy
Lung function
At Weeks 12 and 28, aclidinium improved the baseline-
adjusted mean trough FEV1 compared with placebo in
ACCLAIM/COPD I (by 61 and 67 mL, respectively; both
p < 0.001) and ACCLAIM/COPD II (by 63 and 59 mL,
respectively; both p < 0.001). In both studies, this effect
was maintained over the 52-week study period (Figure 2;
Table 2). In ACCLAIM/COPD I, treatment differences in
trough FEV1 ranged from 60 to 67 mL at all time points
except for Weeks 1 and 4 where the differences were 44
and 37 mL, respectively (p-values ranged from 0.021 to
<0.0001). In ACCLAIM/COPD II, treatment differences
ranged from 51 to 78 mL throughout the study (p-values
ranged from 0.0011 to <0.0001).
Significant improvements in other lung function para-
meters were observed for aclidinium versus placebo
throughout the two studies (Table 2). In both studies,
Patients screened
n = 1313
Patients not randomised
n = 470
Completed
n = 538 (85.8%)
Included for
efficacy analysis
n = 616 (98.2%)
Completed
n = 169 (78.2%)
Included for
efficacy analysis
n = 210 (97.2%)
Aclidinium 200 μg
n = 627 (100%)
Placebo
n = 216 (100%)
Discontinued treatment
n = 89 (14.2%)
Reasons for withdrawal
(% based on randomised patients)
Patient’s request
Adverse event
COPD exacerbation
Lack of efficacy
Protocol non-compliance
Lost to follow-up
Non-fulfilment of entry criteria
Other reasons
29 (32.6%)
24 (27.0%)
13 (14.6%)
12 (13.5%)
6 (6.7%)
3 (3.4%)
1 (1.1%)
1 (1.1%)
Discontinued treatment
n = 47 (21.8%)
Reasons for withdrawal
(% based on randomised patients)
Patient’s request
Adverse event
Lack of efficacy
COPD exacerbation
Protocol non-compliance
Other reasons
16 (34.0%)
13 (27.7%)
8 (17.0%)
7 (14.9%)
1 (2.1%)
2 (4.3%)
Patients randomised
n = 843
COPD: chronic obstructive pulmonary disease.
a)
Patients screened
n = 1456
Patients not randomised
n = 652
Completed
n = 446 (74.3%)
Included for
efficacy analysis
n = 594 (99.0%)
Completed
n = 118 (57.8%)
Included for
efficacy analysis
n = 201 (98.5%)
Aclidinium 200 μg
n = 600 (100%)
Placebo
n = 204 (100%)
Discontinued treatment
n = 154 (25.7%)
Reasons for withdrawal
(% based on randomised patients)
Patient’s request
Lack of efficacy
Adverse event
COPD exacerbation
Lost to follow-up
Protocol non-compliance
Non-fulfilment of entry criteria
Other reasons
40 (6.7%)
34 (5.7%)
29 (4.8%)
22 (3.7%)
11 (1.8%)
8 (1.3%)
4 (0.7%)
6 (1.0%)
Discontinued treatment
n = 86 (42.2%)
Reasons for withdrawal
(% based on randomised patients)
Lack of efficacy
Patient’s request
Adverse event
COPD exacerbation
Lost to follow-up
Protocol non-compliance
Other reasons
36 (17.6%)
17 (8.3%)
13 (6.4%)
10 (4.9%)
6 (2.9%)
3 (1.5%)
1 (0.5%)
Patients randomised
n = 804
b)
Figure 1 Patient disposition in a) ACCLAIM/COPD I, and b)
ACCLAIM/COPD II.
Jones et al. Respiratory Research 2011, 12:55
http://respiratory-research.com/content/12/1/55
Page 3 of 10the median time to peak FEV1 in the aclidinium group
was 2 hours and significantly more patients had an
increase in FEV1 of ≥15% above baseline at 0.25, 0.5, 1,
2 and 3 hours post-dose with aclidinium compared with
placebo (p < 0.0001 at each time point).
An exploratory post-hoc analysis using pooled data from
the two studies was conducted to examine the treatment
differences in trough FEV1 when the patient population
was stratified according to the use of concomitant inhaled
corticosteroids. The magnitude of improvement in trough
FEV1 with aclidinium over placebo was slightly greater in
Table 1 Baseline demographics and disease status (safety population)
ACCLAIM/COPD I ACCLAIM/COPD II
Aclidinium 200 μg
(n = 627)
Placebo
(n = 216)
Aclidinium 200 μg
(n = 600)
Placebo
(n = 204)
Age, mean (SD) years 62.6 (8.2) 61.9 (8.3) 65.1 (8.6) 65.2 (8.6)
Male, n (%) 488 (77.8) 175 (81.0) 383 (63.8) 124 (60.8)
Caucasian, n (%) 627 (100.0) 215 (99.5) 552 (92.0) 189 (92.7)
BMI, mean (SD), kg/m
2 26.4 (4.70) 26.7 (4.65) 26.8 (5.9) 26.6 (6.1)
Current smoker, n (%) 283 (45.1) 98 (45.4) 222 (37.0) 79 (38.7)
Smoking history, mean (SD) pack-years 40.4 (21.0) 38.4 (18.3) 57.8 (29.9) 58.2 (28.4)
Post-bronchodilator FEV1, mean (SD) % of predicted value 54.2 (15.1) 52.9 (15.2) 50.6 (15.6) 49.4 (15.1)
Post-bronchodilator FEV1/FVC ratio, mean (SD) % 49.2 (11.4) 48.9 (11.1) 48.0 (11.7) 47.1 (11.9)
Bronchodilator reversibility, mean (SD) % 12.3 (14.2) 12.9 (14.0) 17.7 (15.7) 17.3 (13.5)
Pre-dose FEV1 on Day 1, mean (SD) L 1.413 (0.514) 1.385 (0.509) 1.214 (0.489) 1.154 (0.479)
SGRQ total score, mean (SD) 47.3 (17.6) 47.3 (18.0) 45.2 (16.8) 47.1 (16.3)
Baseline Dyspnoea Index focal score, mean (SD) 6.3 (2.2) 6.4 (2.2) 6.5 (2.3) 6.2 (2.3)
Pre-study COPD medication, n (%) 532 (84.9) 178 (82.4) 505 (84.2) 177 (86.8)
Inhaled corticosteroids 239 (38.1) 83 (38.4) 228 (38.0) 78 (38.2)
Long-acting b2-agonists 99 (15.8) 34 (15.7) 38 (6.3) 14 (16.9)
Long-acting b2-agonists + inhaled corticosteroids* 170 (27.1) 47 (21.8) 217 (36.2) 76 (27.3)
Long-acting muscarinic antagonist 110 (17.5) 39 (18.1) 103 (17.2) 37 (18.1)
Short-acting b2-agonists 331 (52.8) 95 (44.0) 408 (68.0) 143 (70.1)
Short-acting b2-agonists + short-acting muscarinic agents 98 (15.6) 45 (20.8) 55 (9.2) 25 (12.3)
Short-acting muscarinic agents 99 (15.8) 26 (12.0) 51 (8.5) 28 (13.7)
Xanthines 116 (18.5) 34 (15.7) 29 (4.8) 6 (2.9)
Patients with ≥1 self-reported COPD exacerbation in previous year, n (%)
† 354 (56.5) 131 (60.6) 182 (30.3) 64 (31.4)
*The percentages of patients who received long-acting b2-agonists plus inhaled corticosteroids include those who switched from long-acting b2-agonists plus
inhaled corticosteroids to inhaled corticosteroids prior to screening.
†Data missing for four patients in ACCLAIM/COPD I (two each in the aclidinium and placebo arms).
BMI: body mass index; COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; SGRQ: St George’s
Respiratory Index; SD: standard deviation.
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FEV1: forced expiratory volume in 1 second.
Data reported as least squares means ± standard error.
p-values vs placebo.
1.1
1.2
1.3
1.4
1.5
Placebo
Aclidinium 200 μg
Week 52 Week 28 Week 12 Week 4
ACCLAIM/
COPD II
ACCLAIM/
COPD I
ACCLAIM/
COPD II
ACCLAIM/
COPD I
ACCLAIM/
COPD II
ACCLAIM/
COPD I
ACCLAIM/
COPD II
ACCLAIM/
COPD I
p < 0.05
p < 0.001 p < 0.001 p < 0.001 p < 0.001
p < 0.001 p < 0.001
p < 0.001
Figure 2 Trough forced expiratory volume in 1 second for
aclidinium 200 μg versus placebo over 52 weeks in ACCLAIM/
COPD I and II.
Table 2 Baseline-adjusted mean differences between
aclidinium and placebo on lung function parameters at
all measured time points throughout the 52-week studies
Parameter ACCLAIM/COPD I ACCLAIM/COPD II
Trough FEV1, mL 37-67* 51-78
§
Peak FEV1, mL 147-177
‡ 141-156
‡
AUC(0-3 h), mL 135-166
‡ 133-150
‡
Trough FVC, mL 96-141
§ 83-148
†
Peak FVC, mL 275-310
‡ 259-315
‡
Trough IC, mL 58-101* 64-135
§
Peak IC, mL 166-204
‡ 171-220
‡
Morning PEF, mL/min 6.1-13.9* 9.8-17.2*
Evening PEF, mL/min 18.9-22.8
‡ 16.9-22.9
§
*p < 0.05;
§p < 0.01;
†p < 0.001;
‡p < 0.0001.
Data are reported as the minimum and maximum values over the treatment
period; the indicated p-values apply throughout the stated range.
FEV1: forced expiratory volume in 1 second; AUC(0-3 h): area under the curve
from 0 to 3 h post-dose; FVC: forced vital capacity; IC: inspiratory capacity;
PEF: peak expiratory flow.
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those who did not at Weeks 4 (64 versus 47 mL), 44
(80 versus 48 mL) and 52 (90 versus 48 mL). However,
treatment differences in trough FEV1 were slightly lower
or similar in patients who used inhaled corticosteroids
compared with those who did not at Weeks 12 (52 versus
68 mL) and 28 (65 versus 63 mL).
Quality of life and dyspnoea
In ACCLAIM/COPD I, significantly more patients receiv-
ing aclidinium had an improvement in SGRQ total score
≥4 units compared with placebo at all measured time
points; at 52 weeks, the percentage of patients achieving
this improvement was 48.1% versus 39.5% for aclidinium
versus placebo, respectively (p = 0.025; Figure 3). In
ACCLAIM/COPD II, significantly more patients had an
improvement in SGRQ total score ≥4 units with aclidi-
nium versus placebo up to 44 weeks; at 52 weeks, the per-
centage of patients achieving this improvement was 39.0%
versus 32.8% for aclidinium versus placebo, respectively
(p = 0.074; Figure 3). At Week 52, the mean improvement
from baseline in SGRQ total score was greater for aclidi-
nium compared with placebo in ACCLAIM/COPD I
(-4.63 versus -3.10, respectively; treatment difference 1.53;
p = 0.19) and ACCLAIM/COPD II (-3.49 versus -1.28,
respectively; treatment difference 2.21; p = 0.021). Greater
improvements in baseline-adjusted SGRQ total score were
observed for aclidinium versus placebo throughout both
ACCLAIM/COPD I (range 1.53-2.71; p < 0.05 at Weeks
12 and 28) and ACCLAIM/COPD II (range 2.21-3.54; p <
0.05 at all time points).
In ACCLAIM/COPD I, more patients receiving aclidi-
nium versus placebo exceeded the MCID for TDI focal
score at 52 weeks (56.4% versus 38.0%; odds ratio 2.22;
95% confidence interval [CI] 1.57 to 3.13; p < 0.0001);
similar results were observed at Weeks 12, 28 and 44.
The proportion of patients who exceeded the MCID was
also greater for aclidinium versus placebo at all time
points in ACCLAIM/COPD II, but was significant only at
Week 12 (53.1% versus 42.7%; odds ratio 1.53; 95% CI
1.04 to 2.23; p = 0.029). At Week 52, the mean improve-
ment from baseline in TDI focal score was greater for
aclidinium compared with placebo in ACCLAIM/COPD
I (1.83 versus 0.61; treatment difference 1.22; p < 0.0001)
and ACCLAIM/COPD II (1.61 versus 1.09; treatment dif-
ference 0.52; p = 0.12). Baseline-adjusted mean treatment
differences in TDI focal score favoured aclidinium
throughout the study in ACCLAIM/COPD I (range 0.73-
1.22; p < 0.01 at all time points) and ACCLAIM/COPD II
(range 0.52-1.03; p < 0.01 at Weeks 12, 28 and 44).
Exacerbations
The rate of moderate or severe exacerbations in the pla-
cebo arm was numerically lower in ACCLAIM/COPD I
(0.46 events/patient/year, respectively) than in ACCLAIM/
COPD II (0.80 events/patient/year, respectively). In
ACCLAIM/COPD I, the proportion of patients who
experienced a moderate or severe exacerbation was similar
in the aclidinium and placebo groups (26.6% versus 25.7%,
respectively). There was no significant difference between
the two groups in time to first moderate or severe exacer-
bation (hazard ratio 1.0; 95% CI 0.72 to 1.33; p = 0.9;
Figure 4). In ACCLAIM/COPD II, fewer patients in the
aclidinium group experienced a moderate or severe
exacerbation compared with those in the placebo group
(33.2% versus 39.8%, respectively; rate ratio 0.7; 95% CI
0.55 to 0.90; p = 0.0046). Aclidinium significantly delayed
the time to first moderate or severe exacerbation com-
pared with placebo (hazard ratio 0.7; 95% CI 0.55 to 0.92;
p = 0.01; Figure 4).
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Figure 3 Percentage of patients with a clinically relevant
improvement in St George’s Respiratory Questionnaire total
score (≥4 units) over time in ACCLAIM/COPD I and II.
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COPD: chronic obstructive pulmonary disease.
Figure 4 Kaplan-Meier survival curves for the time to first
moderate or severe chronic obstructive pulmonary disease
exacerbation in ACCLAIM/COPD I and II.
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In ACCLAIM/COPD I, there were no significant dif-
ferences between aclidinium and placebo in patient-
recorded daily symptom scores for breathlessness,
cough, sputum production or wheezing, or use of daily
rescue medication. However, in ACCLAIM/COPD II,
there were significant differences in favour of aclidi-
nium for cough and sputum production (Week 1),
breathlessness (Week 12), wheezing (Week 28) and use
of daily rescue medication (Weeks 12 and 28) (p <
0.05 for all).
Safety
The overall incidence of AEs was similar in the aclidi-
nium and placebo groups for ACCLAIM/COPD I and II
(Table 3). AEs, most of which were mild to moderate in
intensity, were similar between the two groups in both
studies. AEs associated with anticholinergic medication
occurred with an incidence of <1% in both the aclidi-
nium and placebo groups, except for dry mouth (1.0%
versus 0.9% respectively) in ACCLAIM/COPD I, and
urinary tract infection (4.8% versus 4.9%, respectively),
constipation (2.2% versus 2.0%, respectively) and dry
mouth (0.3% versus 1.5%, respectively) in ACCLAIM/
COPD II. AEs reported by ≥2% of patients in either
group of either study and possible anticholinergic AEs
are provided in Tables 4 and 5, respectively.
The incidence of serious adverse events (SAEs) was
similar for aclidinium and placebo in both studies
(Table 3). In ACCLAIM/COPD I, only two patients,
both in the aclidinium group, reported SAEs that
were considered to be treatment-related (angle closure
glaucoma and open angle glaucoma). Six patients in
ACCLAIM/COPD II reported treatment-related SAEs,
of whom four received aclidinium (atrial fibrillation
and sick sinus syndrome, atrial flutter, myocardial
infarction and pneumonia) and two received placebo
(headache and rash [same patient], and cerebellar
infarction). In each study, the percent incidence of
deaths was lower in the aclidinium group than in the
placebo group (Table 3), and none were considered to
be treatment-related.
Cardiac and vascular disorders were reported at a
similar frequency in the aclidinium and placebo groups
o fe a c hs t u d y( T a b l e3 ) .I nA C C L A I M / C O P DI ,o n l y
two patients (one in each group) experienced a cerebro-
vascular accident or ischaemic stroke. Nine patients in
ACCLAIM/COPD II reported a cerebrovascular acci-
dent, cerebral infarction or transient ischaemic attack, of
whom seven (1.2%) received aclidinium and two (1.0%)
received placebo.
No clinically relevant changes in laboratory para-
meters, vital signs or ECG results (including QTc inter-
vals) were observed in either group in either study.
Discussion
These studies show that aclidinium 200 μgo n c e - d a i l y
improves lung function in patients with moderate to
severe COPD. Compared with placebo, aclidinium
improved the adjusted mean trough FEV1 by 60 to 67 mL
at all time points after 4 weeks in ACCLAIM/COPD I,
and by 51 to 78 mL throughout the treatment period in
ACCLAIM/COPD II. The slight decrease in the trough
FEV1 response with aclidinium over time does not appear
to be related to tachyphylaxis, as a similar decline
occurred with placebo in both studies. There were some
small differences in the patient demographics between
the studies, perhaps the most relevant being a lower
mean bronchodilator reversibility in ACCLAIM/COPD I
compared with ACCLAIM/COPD II. Despite this differ-
ence, the improvements in trough FEV1 were similar.
These trough FEV1 improvements are smaller than those
seen in previous studies of aclidinium 200 μg [7] and tio-
tropium [14-20], where the magnitude of improvement
ranged from 100 to 150 mL. Interestingly, in the recent
UPLIFT trial (n = 5993), reported differences in trough
FEV1 between tiotropium and placebo were smaller, ran-
ging from 87 to 103 mL [21]. In the ACCLAIM/COPD
and UPLIFT trials, patients were allowed to use inhaled
corticosteroids as concomitant therapy, while in UPLIFT,
Table 3 Adverse-event profile in ACCLAIM/COPD I and II
ACCLAIM/COPD I ACCLAIM/COPD II
Aclidinium 200 μg
(n = 627)
n (%)
Placebo
(n = 216)
n (%)
Aclidinium 200 μg
(n = 600)
n (%)
Placebo
(n = 204)
n (%)
Total AEs 355 (56.6) 128 (59.3) 479 (79.8) 154 (75.5)
SAEs 50 (8.0) 22 (10.2) 62 (10.3) 23 (11.3)
Deaths 7 (1.1) 4 (1.9) 6 (1.0) 3 (1.5)
Cardiac disorders* 32 (5.1) 14 (6.5) 41 (6.8) 17 (8.3)
Vascular disorders* 22 (3.5) 14 (6.5) 34 (5.7) 12 (5.9)
*System organ classes.
COPD exacerbations were reported as part of the efficacy evaluations and, unless life-threatening, were not considered to be AEs.
AEs: adverse events; COPD: chronic obstructive pulmonary disorder; SAEs: serious adverse events.
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Page 6 of 10Table 4 Adverse events reported by ≥2% of patients in any treatment group in ACCLAIM/COPD I or ACCLAIM/COPD II
Adverse event preferred term ACCLAIM/COPD I ACCLAIM/COPD II
Aclidinium 200 μg
(n = 627)
n (%)
Placebo
(n = 216)
n (%)
Aclidinium 200 μg
(n = 600)
n (%)
Placebo
(n = 204)
n (%)
Nasopharyngitis 102 (16.3) 31 (14.4) 76 (12.7) 23 (11.3)
Headache 71 (11.3) 27 (12.5) 85 (14.2) 26 (12.7)
Upper respiratory tract infection 8 (1.3) 3 (1.4) 65 (10.8) 20 (9.8)
Back pain 30 (4.8) 10 (4.6) 40 (6.7) 15 (7.4)
Diarrhoea 17 (2.7) 1 (0.5) 42 (7.0) 8 (3.9)
Pharyngolaryngeal pain 21 (3.3) 3 (1.4) 25 (4.2) 11 (5.4)
Urinary tract infection 5 (0.8) 2 (0.9) 29 (4.8) 10 (4.9)
Cough 29 (4.6) 8 (3.7) 29 (4.8) 8 (3.9)
Hypertension 9 (1.4) 9 (4.2) 27 (4.5) 6 (2.9)
Sinusitis 5 (0.8) 1 (0.5) 27 (4.5) 9 (4.4)
Dyspnoea 12 (1.9) 5 (2.3) 17 (2.8) 9 (4.4)
Arthralgia 17 (2.7) 1 (0.5) 24 (4.0) 5 (2.5)
Influenza 21 (3.3) 4 (1.9) 22 (3.7) 8 (3.9)
Pain in extremity 5 (0.8) 3 (1.4) 23 (3.8) 4 (2.0)
Dizziness 15 (2.4) 6 (2.8) 19 (3.2) 7 (3.4)
Abdominal pain 6 (1.0) 3 (1.4) 20 (3.3) 0 (0.0)
Muscle spasms 4 (0.6) 0 (0.0) 19 (3.2) 5 (2.5)
Musculoskeletal pain 7 (1.1) 1 (0.5) 19 (3.2) 3 (1.5)
Pneumonia 12 (1.9) 7 (3.2) 10 (1.7) 4 (2.0)
Rhinitis 12 (1.9) 7 (3.2) 14 (2.3) 4 (2.0)
Myalgia 3 (0.5) 3 (1.4) 18 (3.0) 3 (1.5)
Oedema peripheral 7 (1.1) 2 (0.9) 18 (3.0) 2 (1.0)
Chest pain 5 (0.8) 1 (0.5) 10 (1.7) 6 (2.9)
Insomnia 7 (1.1) 1 (0.5) 8 (1.3) 6 (2.9)
Nausea 8 (1.3) 3 (1.4) 16 (2.7) 6 (2.9)
Viral infection 9 (1.4) 6 (2.8) 5 (0.8) 3 (1.5)
Bronchitis 4 (0.6) 1 (0.5) 10 (1.7) 5 (2.5)
Depression 3 (0.5) 3 (1.4) 15 (2.5) 4 (2.0)
Blood glucose increased 3 (0.5) 4 (1.9) 3 (0.5) 5 (2.5)
Epistaxis 5 (0.8) 0 (0.0) 8 (1.3) 5 (2.5)
Neck pain 7 (1.1) 0 (0.0) 6 (1.0) 5 (2.5)
Procedural pain 1 (0.2) 1 (0.5) 5 (0.8) 5 (2.5)
Vomiting 7 (1.1) 0 (0.0) 15 (2.5) 5 (2.5)
Contusion 11 (1.8) 3 (1.4) 14 (2.3) 1 (0.5)
Rash 2 (0.3) 0 (0.0) 14 (2.3) 3 (1.5)
Toothache 12 (1.9) 5 (2.3) 12 (2.0) 2 (1.0)
Constipation 4 (0.6) 0 (0.0) 13 (2.2) 4 (2.0)
Gamma-glutamyl transferase increased 13 (2.1) 2 (0.9) 2 (0.3) 3 (1.5)
Angina pectoris 4 (0.6) 3 (1.4) 3 (0.5) 4 (2.0)
Fatigue 4 (0.6) 1 (0.5) 10 (1.7) 4 (2.0)
Lower respiratory tract infection 5 (0.8) 0 (0.0) 5 (0.8) 4 (2.0)
Musculoskeletal chest pain 7 (1.1) 1 (0.5) 12 (2.0) 4 (2.0)
Pain 0 (0.0) 0 (0.0) 6 (1.0) 4 (2.0)
Pyrexia 8 (1.3) 3 (1.4) 12 (2.0) 1 (0.5)
Rhinorrhoea 2 (0.3) 1 (0.5) 9 (1.5) 4 (2.0)
Syncope 1 (0.2) 0 (0.0) 2 (0.3) 4 (2.0)
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authors speculated that concomitant therapy may have
diminished the measured treatment effect [21], and it is
possible that a similar effect operated in the ACCLAIM/
COPD trials, although perhaps to a lesser extent, given
that long-acting b-agonists were not permitted in these
studies. This hypothesis cannot be tested reliably by a
subgroup analysis to compare patients with or without
concomitant inhaled corticosteroids, because it is not
possible to remove the potential confounding effect of
underlying disease severity having influenced the physi-
cian’s decision to treat with inhaled corticosteroids.
Pooled post-hoc analyses of the ACCLAIM/COPD stu-
dies suggested that patients who used inhaled corticoster-
oids during aclidinium treatment showed greater
bronchodilation than those who did not, but these differ-
ences were not consistent over time.
As FEV1 correlates poorly with health status and COPD
symptoms [22], it is important to directly investigate the
effects of therapy on these parameters. At all time points
in ACCLAIM/COPD I, significantly greater proportions of
patients with aclidinium versus placebo exceeded the
MCID for SGRQ total score and TDI focal score, and
therefore may be considered to have achieved clinically
significant improvements in health status and dyspnoea.
In ACCLAIM/COPD II, significantly greater proportions
of patients with aclidinium versus placebo exceeded the
MCID for SGRQ total score up to Week 44 and TDI focal
score at Week 12. The lack of a statistically significant dif-
ference in SGRQ total score at Week 52 in ACCLAIM/
COPD II may be due to the higher rate of dropouts with
placebo versus aclidinium, resulting in a greater propor-
tion of ‘healthy survivors’ remaining in the placebo arm
and reducing the treatment differences observed with acli-
dinium. In Figure 3, it can be seen that the percentage of
placebo-treated patients with an SGRQ improvement ≥4
units increased over time in ACCLAIM/COPD II (24.1-
32.8%), but remained relatively constant in ACCLAIM/
COPD I (36.0-40.0%).
Aclidinium significantly delayed the time to first mod-
erate or severe exacerbation compared with placebo in
ACCLAIM/COPD II, but not in ACCLAIM/COPD I. A
possible reason for this variation may be the lower rate of
moderate or severe exacerbations in the placebo group in
ACCLAIM/COPD I compared with ACCLAIM/COPD II
(0.46 versus 0.80 events/patient/year, respectively). The
placebo exacerbation rate in ACCLAIM/COPD II was
similar to that observed in a 1-year study of tiotropium
(0.95 events/patient/year) [15] and in the UPLIFT study
(0.85 events/patient/year) [21], both of which also
reported significant treatment effects on exacerbations.
As significant effects on exacerbation are more likely to
be shown in populations with frequent exacerbations, the
low exacerbation rate in ACCLAIM/COPD I may explain
the lack of difference observed between aclidinium and
placebo. It should be noted that the study was not pow-
ered for exacerbations and the population was not
enriched by recruiting patients with a history of exacer-
bation in the year before entry. The difference in rates
also cannot be explained entirely in terms of demo-
graphic differences, chiefly a higher proportion of women
and a greater smoking history in ACCLAIM/COPD II.
While the reasons remain unknown, we postulate that
the difference may be related to the fact that exacerba-
tions were defined based on healthcare utilisation (i.e.
moderate exacerbation; use of oral corticosteroids and/or
Table 5 Patients with ≥2 possible anticholinergic adverse events in any group in ACCLAIM/COPD I or ACCLAIM/COPD
II (by system organ class and preferred term)
System organ class Adverse event preferred term ACCLAIM/COPD I ACCLAIM/COPD II
Aclidinium 200 μg
(n = 627)
n (%)
Placebo
(n = 216)
n (%)
Aclidinium 200 μg
(n = 600)
n (%)
Placebo
(n = 204)
n (%)
Atrial fibrillation 3 (0.5) 2 (0.9) 3 (0.5) 0 (0.0)
Atrial flutter 0 (0.0) 0 (0.0) 2 (0.3) 1 (0.5)
Cardiac disorders Sinus tachycardia 2 (0.3) 1 (0.5) 1 (0.2) 0 (0.0)
Tachycardia 3 (0.5) 0 (0.0) 3 (0.5) 1 (0.5)
Ventricular extrasystoles 1 (0.2) 1 (0.5) 3 (0.5) 0 (0.0)
Dry eye 1 (0.2) 1 (0.5) 5 (0.8) 0 (0.0)
Eye irritation 0 (0.0) 0 (0.0) 3 (0.5) 1 (0.5)
Eye disorders Eye pain 3 (0.5) 0 (0.0) 0 (0.0) 0 (0.0)
Vision blurred 0 (0.0) 0 (0.0) 3 (0.5) 1 (0.5)
Visual acuity reduced 0 (0.0) 0 (0.0) 2 (0.3) 1 (0.5)
Gastrointestinal disorders Constipation 4 (0.6) 0 (0.0) 13 (2.2) 4 (2.0)
Dry mouth 6 (1.0) 2 (0.9) 2 (0.3) 3 (1.5)
Infections and infestations Urinary tract infection 0 (0.0) 0 (0.0) 29 (4.8) 10 (4.9)
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patient hospital treatment); however, differences in
healthcare resource utilisation do not appear to have
caused any disparity in exacerbation rates in previous
studies conducted in different territories.
In accordance with previous Phase I/II studies
[6-8,23], aclidinium was safe and well tolerated in these
Phase III studies. The percentages of SAEs, cardiovascu-
lar events and deaths with aclidinium were either similar
or lower than those with placebo. Pooled analyses of
safety data from tiotropium trials have indicated that,
compared with placebo, tiotropium is associated with an
excess risk of dry mouth, urinary retention and arrhyth-
mias [24,25]. In the ACCLAIM/COPD studies, the inci-
dence of anticholinergic AEs was similar between the
two groups. Although safety analyses of aclidinium have
not yet been conducted across multiple studies in a
pooled analysis as for tiotropium, the initial evidence
suggests that aclidinium may offer a low potential for
class-related systemic side effects.
Conclusions
Treatment with aclidinium 200 μg once-daily is safe and
improves lung function and symptomatic endpoints in
patients with moderate or severe COPD. The clinical
relevance of the observed improvements in trough FEV1
is uncertain, as a minimum clinically important differ-
ence in trough FEV1 has not yet been established. Some
authors have suggested an improvement of about 100-
120 mL as a possible benchmark, but this is expert opi-
nion rather than a validated parameter [22,26]. There is
evidence that treatment differences in trough FEV1
values have been decreasing in recent trials due to
changes in the availability of concomitant medications
and baseline patient populations over time [27]. Regula-
tors may consider a change of 5-10% from baseline
FEV1 to be clinically meaningful [22]; assuming a base-
line FEV1 of 1.29 L (the mean across treatment arms in
this study), this corresponds to an increase of 64-129
mL. Additional clinical studies of aclidinium are
ongoing in patients with moderate to severe COPD to
investigate both higher and/or twice-daily dosing that
could offer improvements on the efficacy profile com-
pared with the 200 μg once-daily dose. In a Phase II,
placebo- and active comparator-controlled study, aclidi-
nium 400 μg twice-daily provided bronchodilation over
24 hours that was statistically superior and clinically
meaningful compared with placebo, and comparable
with tiotropium 18 μg once-daily [28]. Early Phase III
data suggest that aclidinium 200 μg and 400 μgt w i c e -
daily for 12 weeks both provide statistically and clinically
significant improvements in lung function compared
with placebo [29].
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